

Global Robotics Institute - Celebration

Robotic Radical Prostatectomy Lessons Learned: 3000 Cases






Vipul R. Patel MD
Director. Global Robotics Institute
Assoc Professor of Urology @ Univ of Central Florida
Director of Urologic Oncology

Evolution

- Evolution of open radical prostatectomy over 100 years:
 - H H Young 1905
 - P Walsh 1979
- Robotic radical prostatectomy relatively new:
 - First performed in 2000 by J. Binder in Germany
 - approximately 300,000 total
- Where are we today?



What Is The Status Of RALP Today?

What is the status of RALP today?

Have acceptable outcomes been achieved?

What are the key principles in achieving the trifecta

• How can we continue to improve our results?



Goals and Expectations

- Initial goals for robotic prostatectomy (2000)
 - establish a viable minimally invasive option
 - attempt to make laparoscopic prostatectomy a feasible option for a larger number of surgeons and patients
 - Primitive instrumentation and a primitive approach
- What we achieved was beyond our initial expectations:
 - The approach and expectations of robotic prostatectomy have evolved significantly



RALP: Perioperative outcomes

Authors	Year	Patients	Median/ Mean Age	Mean BMI	Pre-op	Clinical Stage		Operative	Mean EBL	%	Open	Hospital Length of	Complication
	Teal	(N)		Weall Divil	PSA	T1c	T2	Time. min	Weall LBL	Transfused	Conversion	Stay (days)	Rate
Hu [14]	2006	322	62.1	27.5	-	74.50%	24.80%	186	250	1.60%	0%	-	14.60%
Joseph [15]	2006	325	60	-	6.6	81.00%	19.00%	130	196	1.30%	0.00%	-	8.60%
Badani [16]	2007	2766	60.2	27.6	6.4	77.30%	22.00%	154	142	1.50%	0.10%	1.14	12.20%
Mottrie [17]	2007	184	62	-	8.7	-	-	171	200	0.5%	0.54%	-	11.9%
Rozet [18]	2007	133	62	24.8	7.6	57.1%	42.8%	166	609	3%	0%	5.4	19.4%
Nelson [19]	2007	629	59.3	-	6.4	-	-	-	-	-	-	1.17	17%
Borin [20]	2007	400	61.2	26.8	6.6	68%	26.5%	-	103.5	-	-	1	-
Zorn [21]	2007	744	59.6	28.1	6.6	74%	26%	234	222	1.20%	1.20%	1.2	-
Wood [22]	2007	117	60.2	-	6.5	-	-	210	151	-	-	1.2	-
Schroeck [23]	2008	362	59.2	27.8	5.4	83.10%	16.90%	-	150	-	1.60%	-	-
Chan [24]	2008	660	60	-	6.8	75.30%	24.70%	207	140	0.80%	0.90%	1.3	-
Patel [25]	2008	1500	61	30.5	6.1	78%	20%	105	111	0.50%	0	1.1	4.30%
Krambeck [26]	2009	294	61	-	4.9	72.8%	26.9%	236	-	5.1%	-	-	4.8%
Murphy [27]	2009	400	60.2	27.2	7	69.70%	30.30%	186	-	2.50%	0.30%	3.1	15.70%
Rocco [28]	2009	120	63	-	6.9	69%	31%	215	200	-	-	3	-
Ham[29]	2009	321	63.5	24.3	29.7	-	-	219	402	-	-	5.3	5.3%
Weighted means			60.5	28	7.32	72.6%	19.2%	166.6	169.1	1.39%	0.34%	1.55	10.5%



Our Experience With RALP

First RALP in 2002

- Prostatectomies performed: 3300 +
- Average age 61yrs (31-80)
- Median Gleasons score 6 (5-10)
- Median PSA 6.9ng/dl (0.5-50)



Peri-Operative Outcomes

- Average OR time 91 minutes (35-365)
- Average EBL: 100 cc (50-500)
- Average LOS: 1.2 days (1-14)

- Complications: 4.2%
 - Transfusions: 0.3%
 - Conversions: 0.1%





RALP Lessons Learned: The Trifecta:


Cancer Control
Urinary Continence
Sexual Function



Factors That May Influence The Trifecta

- Experience of the surgeon
- Tumor status of the patient
- Co-Morbidities
- Complications
- Approach to key portions of the operation:
 - Apical dissection
 - Neurovascular bundle preservation





The Trifecta:

Cancer Control Urinary Continence Sexual Function



RALP: Oncologic outcomes

Authors	Year	Patients (N)		Pathologic Staging	9	Positive Surgical Margins		
Authors	rear		pT2	pT3	pT4	pT2	pT3	Overall
Joseph [15]	2006	325	81.00%	19.00%	-	-	-	13.00%
Atug [34]	2006	140	87.9%	9.3%	2.8%	18%	53.8%	18.5%
Badani [16]	2007	2766	77.70%	22.00%	0.30%	13.00%	35.00%	12.30%
Rozet [18]	2007	133	88.5%	11.5%	0	13%	20.9%	19.5%
Mottrie [17]	2007	184	62.5%	37.5%	0	2.5%	37.1%	15.7%
Zorn [21]	2007	744	-	-	-	12.90%	44.80%	18.80%
Borin[20]	2007	400	73.5%	26	5%	6.1%	31.9%	12.5%
Tewari [35]	2008	700	83.5%	13.6%	2.9%	5.4%	-	-
Schroeck [23]	2008	362	79.30%	20.70%	0	-	-	29.30%
Chan [24]	2008	660	80.60%	19.40%	0	11.30%	45.00%	17.90%
Liss [36]	2008	216	68.5%	31.5%	0	5.4%	33%	14.8%
Patel [25]	2008	1500	78.30%	19.50%	1.50%	4.00%	34.00%	9.30%
Murphy [27]	2009	400	70%	29.80%	0.20%	9.60%	42.30%	19.20%
Krambeck[26]	2009	294	90.1%	9.5	9%	-	-	15.6%
Rocco[28]	2009	120	73%	24%	3%	17%	34%	22%
Ham [29]	2009	321	55.1%	43.7%	1.2%	-	-	33.3%
Weighted Means			77.4%	21.9%	0.7%	9.6%	37.1%	15.2%




Histopathology

- 3000 Cases
- Median Gleason's score: 6 (5-10)
- Mean prostate weight = 50 gms (15- 420)
- Pathologic Staging:
 - T2: 78 %
 - T3: 21.9 %
 - T4: 0.1 %






Margin Positive Rate @ 3000 cases




PSM - Location





PSM - % Tumor Surgical Specimen





Multivariable Analysis Independent predictive factor for PSM

Predictive Factor	Comparison	Chi-square p-value	Odds Ratio (95% CI)				
Pre-operative variables							
Clinical Stage	T2 vs T1	< 0.0001	2.9 (1.9 - 4.6)				
	T3 vs T1	< 0.0001	10.7 (2.6 - 43.8)				
Pre-op, intra-op and pos	st-operative variable	s combined					
Percentage of Tumor	continuous	0.0022	8.7 (2.2 - 34.5)				
Pathological Stage	PT3 vs PT2	< 0.0001	3.8 (2.4 - 6.1)				
	PT4 vs PT2	0.0045	27.9 (2.8 - 277.8)				



Independent predictive factors for apex and posterolateral PSM locations

Predictive Factor *	Comparison	Chi-square p-value	Odds Ratio (95% CI)
Apex Location			
ВМІ	continuous	0.0119	1.1 (1.0 - 1.3)
EPE	0 vs 1	0.0032	5.3 (1.7 - 15.9)
Posterolateral Locatio	n		
ВМІ	continuous	0.0321	0.89 (0.79 – 0.99)



Multivariate Analysis

- Independent predictive factors
- Clinical stage
- Pathologic stage
- Percentage of tumor burden



Predictive Factors

- What we operate on is the most important factor during our advanced learning curve
- Clinical stage >T1c, High tumor burdens > 25%, pathologic stage >T2

 Non-predictive factors: Gleason's grade, preop PSA, tumor location, BMI, prostate size



The Trifecta:

Cancer Control Urinary Continence Sexual Function



Post Prostatectomy Urinary Incontinence

• AUA Guidelines: The reported risk of urinary incontinence following prostate cancer therapies ranged from 3% to

74% for radical prostatectomy.

EAU Guidelines: urinary incontinence persists after 1 year in 7.7%





RALP: Continence outcomes


Authors	year	Patients (N)	Median/ Mean Age	Follow-up (months)	Immediate	1 month	3 month	6 month	12 month
Joseph [15]	2006	325	60	6	24%	56%	93%	96%	-
Menon [39]	2007	1142	60.2	12	-	-	-	-	92.00%
Mottrie [17]	2007	184	62	6	-	43%	-	95%	-
Borin[20]	2007	400	61.2	6	-	70.5%	89%	97%	-
Zorn [40]	2007	300	59.4	24	-	23.00%	47.00%	68.00%	90.00%
Patel [37]	2007	500	63.2	12	27%	-	89%	95%	97%
		214 (NR)	64.3	13	13.1%	35.2%	50.2%	61.9%	82.1%
Tewari[35]	2008	304 (AR)	62.8	13	27%	59%	76.6%	85.6%	91.2%
		182 (TR)	61.2	6	38.4%	82.5%	91.3%	97.1%	-
Murphy [27]	2009	395	60.2	>18	-	-	-	-	91.40%
Krambeck[26	2009	294	61	12	-	-	-	-	91.8%
Rocco[28]	2009	120	63	12	-	-	70%	93%	97%
Van der Poel[41]	2009	151	60	12	-	-	-	54% (any loss of urine)	70% (any loss of urine)
Weighted Means			61.15%		25.7%	53.2%	78.6%	86.4%	91%

The Most Important Question Is Which Patients Are At Risk For Long Term Incontinence?


- Despite all of the technical innovations patients recover continence at variable rates and some not at all
- Who are these outliers?
- Can we predict pre-operatively the characteristics?
- What can we do to improve their chances?



Techniques To Improve Early Recovery Of Urinary Continence











Key Surgical Principles




Two functionally independent areas have been




Key Surgical Principles




Peri-Urethral Suspension Stitch






Peri-Urethral Suspension Stitch



Peri-Urethral Suspension Stitch





Patients Characteristics

Patients' Characteristics	No-Suspension	Suspension	p-value
Age – years- Median/ mean ±SD (range)	60/60,1± 6.79	60/59.8 ± 7.48	0.699
mean 200 (range)	(45-73)	(42-79)	
BMI, kg/m2	28.75± 3,59	28.19± 3.61	0.243
	(20-38)	(20-370	
PSA level before RALP,	6.03 ± 5.03	5.52 ± 3.46	0.502
ng/mL - mean ±SD (range)	(0,6-16,3)	(0.5 -13.3)	
Prostate weight (gr)	51.84 ± 22.9	52.18 ± 23.4	0.610
mean ±SD (range)	(15.3 – 96.6)	(23-155)	
AUA-SS - mean ±SD	7.61±7.55	8.21 ± 7.24	0.410
(range)	(0-35)	(0-32)	
Biopsy Gleason Score			
≤6	48/94(51%)	142/237 (60%)	0.192
7	40/94 (42.6%)	78/237 (33%)	0.127
≥ 8	6/94 (6.4%)	17/237 (7%)	0.988



Perioperative Parameters

Perioperative parameters	Non-Suspension	Suspension	p-value
Operative time (min)	77,34 ± 11,81 (55- 100)	76,28 ± 9,54 (45- 100)	0.804
Estimated blood loss (ml)	121,86 ± 54,82 (75-500)	114,02 ± 32,31 (50- 400)	0.265
Transfusion rate (%)	0	0	
Catheterization time (days)	5.33 ± 0.72 (4-8)	5.37 ± 1.3 (4-12)	0.110
Nerve-Sparing Procedure			
Bilateral nerve-sparing	58 (61.7%)	150 (63.3%)	0.886
Unilateral nerve-sparing	20 (21.3%)	45 (19%)	0.749
Non nerve-sparing	16 (17%)	42 (17.7%)	0.895



Pathological stage and positive surgical margins

	No-Suspension	Suspension	p-value
Pathologic Stage			
pT2	68/94 (72.3%)	184/237 (77.6%)	0.381
рТ3	26/94 (27.6%)	53/237 (22.3%)	0.381
PSM rates	9/94 (9.5%)	29/237 (12.2%)	0.621
pT2	3/68 (5.3%)	12/184 (6.5%)	0.743
рТ3	6/26 (23%)	11/53 (20%)	0.989
PSM at the apex	4/94 (4.2%)	15/237(6.3%)	0.639
Gleason Score-Surgical Specimen			
≤6	40/94(42.6%)	105/237 (44.3%)	0.868
7	43/94 (45.7%)	106/237 (44.7%)	0.372
≥ 8	11/94 (11.7%)	26/237 (11%)	0.998



Continence rates

Follow-up time	Without suspension	With suspension	<i>p</i> -value
	stitch (N=94)	stitch (N=237)	
1 month	31 (33.0%)	95 (40.0%)	0.282
3 months	78 (83.0%)	220 (92.8%)	0.013
6 months	89 (94.7%)	232 (97.9%)	0.237
12 months	90 (95.7%)	232 (97.9%)	0.479

Accepted for publication in European Urology May 2009




Prostate Cancer

Periurethral Suspension Stitch During Robot-Assisted Laparoscopic Radical Prostatectomy: Description of the Technique and Continence Outcomes

Vipul R. Patel a,b,*, Rafael F. Coelho a,b,c, Kenneth J. Palmer a,b, Bernardo Rocco a,b,d

European Urology 2009





^a Global Robotics Institute, Florida Hospital Celebration Health, Celebration, FL 34747, USA

^b University of Central Florida School of Medicine, Orlando, FL 32826-0116, USA

^e Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, Divisão de Urologia, São Paulo, Brazil


^d Divisione di Urologia Istituto Europeo di Oncologia, Milano, Italy

Posterior Reconstruction

- First introduced by Rocco et al.
 - Open surgical approach
 - Reconnecting Denonvilliers fascia
 - Attaching posterior bladder neck to urethra
- Technical modifications to robotics:
 - Continuous suture
 - Second layer through bladder neck




First Layer of Reconstruction







2nd Layer of Reconstruction



Combined Anterior & Posterior Reconstruction









Patients' Characteristics	No- Suspension	Suspension	p-value (Suspension	Susp. plus Posterior Reconst.	p-value (Susp. Vs. Susp. +
Age – years	60/60,1± 6.79	60/59.8 ± 7.48	Vs.No-Susp) 0.699	61/60.2 ± 7.4	Posterior) 0.141
Median/mean ± SD (range)	(45-73)	(42-79)		(41-79)	
BMI, kg/m2	28.75± 3,59 (20-38)	28.19± 3.61 (20-370)	0.243	27.6 ±3.8 (17-50)	0.145
PSA ng/mL	6.03 ± 5.03 (0,6-16,3)	5.52 ± 3.46 (0.5 -13.3)	0.502	5.6±4.0 (0.21-46)	0.758
mean±SD (range)					
Prostate weight (gr)	51.84 ± 22.9 (15.3 – 96.6)	52.18 ± 23.4 (23-155)	0.610	52.5±25.6 (22-413)	0.319
mean ±SD (range)					
AUA-SS -	7.61±7.55 (0-35)	8.21 ± 7.24 (0-32)	0.410	8.39±6.5 (0-35)	0.872
mean ±SD (range)					
Biopsy Gleason Score					
≤6	48/94(51%)	142/237 (60%)	0.192	279 (58.9%)	0.333
7	40/94 (42.6%)	78/237 (33%)	0.127	157 (33.2%)	0.667
≥ 8	6/94 (6.4%)	17/237 (7%)	0.988	37 (7.9%)	0.667



Perioperative Parameters

Perioperative parameters	Non-Suspension	Suspension	p-value (Suspension Vs.No-Susp)	Suspension plus Posterior Reconst.	p-value (Susp. Vs. Susp. plus Post.)
•	77,34 ± 11,81 (55-100)	76,28 ± 9,54 (45-100)	0.804	75/78.3±11.4 (50-120)	0.053
	121,86 ± 54,82 (75-500)	114,02 ± 32,31 (50-400)	0.265	117 ± 32 (50-300)	0.102
Fransfusion rate (%)	0	0		0	
	5.33 ± 0.72 (4-8)	5.37 ± 1.3 (4-12)	0.110	5.53±1.3 (4-10)	0.388
Nerve-Sparing					
Bilateral NS	58 (61.7%)	150 (63.3%)	0.886	72 (15 50/)	0.637
Jnilateral NS	20 (21.3%)	45 (19%)	0.749		0.627
Non NS	16 (17%)	42 (17.7%)	0.895	, ,	0.587
	Derative time (min) Estimated blood loss (ml) Transfusion rate (%) Catheterization time (days) Nerve-Sparing Bilateral NS Unilateral NS	Departive time (77,34 ± 11,81 (55-100) Estimated blood loss (75-500) Fransfusion rate (%) 0 Catheterization time (3.3 ± 0.72 (4-8) Nerve-Sparing (58 (61.7%) Bilateral NS (61.7%) Juilateral NS (16 (17%)	Deparative time (77,34 ± 11,81 (76,28 ± 9,54 (45-100)) Estimated blood loss (75-500) (75-500) (50-400) Fransfusion rate (%) 0 0 Catheterization time (4-8) (4-12) Nerve-Sparing 58 (61.7%) 150 (63.3%) Juilateral NS 20 (21.3%) 45 (19%) Juilateral NS 16 (17%) 42 (17.7%)	Deparameters (Suspension Vs.No-Susp) (Suspension Vs.No-Susp)	Department of the plus Posterion (Suspension Vs.No-Susp) Departive time (77,34 ± 11,81 (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (55-100) (50-120) (50-1

Pathological Stage and Positive Surgical Margins


		N o -	Suspension	p-value	Suspension plus	p-value
		Suspension		(Suspension	Posterior	(Susp. Vs. Susp. plus
				Vs.No-Susp)	Reconstruction	Posterior)
					Reconstruction	
SALINO.	Pathologic Stage					0.19
	pT2					
	pT3			0.381	393(83%)	
		68/94 (72.3%)	184/237 (77.6%)	0.381	80 (17%)	
		26/94 (27.6%)	53/237 (22.3%)			
	Overall PSM	9/94 (9.5%)	29/237 (12.2%)	0.621	54/473 (11.4%)	0.912
	PSM - pT2		12/184 (6.5%)	0.743	28/393 (7.1%)	0.823
			` ′		, ,	
	PSM - pT3	3/68 (5.3%)		0.989	26/78 (33.3%)	0.672
0			11/53 (20%)			
-		6/26 (23%)				



Continence rates

Follow-up time	No-Suspension	Suspension	p-value	Suspension plus	p-value		
			(Suspension	Posterior	(Susp. Vs. Susp.		
			Vs.No-Susp)	Reconstruction	plus Posterior)		
1 month	31/94 (33.0%)	95/237 (40.0%)	0.282	244/473 (51.6%)	0.005		
3 months	78/94 (83.0%)	220/237 (92.8%)	0.013	431/473 (91.1%)	0.527		
6 months	89/94 (94.7%)	232/237 (97.9%)	0.237	459/473 (97%)	0.678		





The Trifecta:


Cancer Control
Urinary Continence
Sexual Function



Nerve Sparing

Athermal, atraumatic nerve preservation

- Advantages of robotics:
 - Pneumoperitoneum
 - Visualization- 3D, 10x
 - Dexterity of instrumentation- 7 dof






RALP: Potency Outcomes

Authors	Year	Patients (N)	Median/Mean Age	Type of Nerve Sparing			Follow- up	Potency		Overall Potency Rates after Nerve-sparing procedure (considering bilateral AND unilateral NS)			
				Unilateral	Bilateral	NNS	(months)	Unilateral NS	Bilateral NS	3 month	6 month	12 month	>18 month
Joseph [15]	2006	325	60	23,6%	70%	6,4%	12	58%	80,60%	-	77,1%	-	-
Menon [39]	2007	1142	60,2	25,00% (unilateral veil)	33,00% (bilateral veil)		>18	-	100%	-	-	70% (bilateral veil NS)	100% (bilateral veil NS)
Mottrie [17]	2007	184	62	13%	64,5%	18,1%	6	47%	70%	-	66,6%	-	-
Zorn [40]	2007	300	59,4	26,40%	59,60%	14%	24	62,00%	83,00%	47%	58%	74%	76,5%
Patel [37]	2007	500	63,2	-	-	-	12	-	-	-	-	78%	-
Tewari [49]	2008	215	60	11%	85%	4%	12	-	87%	-	-	-	-
Krambeck[26]	2009	294	61	91	%	9%	12	-	-	-	-	70%	-
Rocco[28]	2009	120	63	-	-	-	12	-	-	31%	43%	61%	-
Murphy[27]	2009	395	60,2	28,2% of potent men	65,3% of potent men	-	12	-	-	-	-	62%	-
Finley[50]	2009	42 (using cautery)	56,5	26%	74%	-	>18	50%	67,8%	8,3%	14,7% (9 months)	43,2%	63,1%
	2003	62 (cautery free)	57	26%	74%	-	>18	80%	93%	32,1%	57,1% (9 months)	76,6%	89,6%
Van der Poel [51]	2009	107	59,6	45,8%	54,2%	-	6	40,8%	63,8%	-	53%	-	-
Weighted Means			60.6	23.5%	53.2%			56.4%	89.3%	38.4%	61.1%	71.2%	94%



Open Approach: Retrograde NVB Dissection



Techniques To Improve Early Recovery Of Sexual Function





My Approach To Nerve Preservation

- Approaches to prostatic pedicle:
 - Antegrade approach with early retrograde release of NVB's

- Approaches to fascia:
 - Interfascial or incremental

- Thermal or athermal:
 - Athermal-clip





J Robotic Surg (2009) 3:13–17 DOI 10.1007/s11701-009-0127-9

ORIGINAL ARTICLE

Athermal early retrograde release of the neurovascular bundle during nerve-sparing robotic-assisted laparoscopic radical prostatectomy

Geoffrey Coughlin · Pankaj P. Dangle · Kenneth J. Palmer · Srinivas Samevedi · Vipul R. Patel




Return Of Sexual Function

- Use of validated questionnaires:
 - SHIM, EPIC, IIEF
- Definition of potency
 - with or without PDE 5
 - Questions 2 and 5 of SHIM
 - Scale of 1-5, Potent if greater than or equal to 4
 - Ability to achieve an erection and have satisfactory intercourse much more that half of the time




Bilateral Retrograde Nerve Sparing Patient Pre-op SHIM > 21






Bilateral Retrograde Nerve Sparing Patient Pre-op SHIM > 21





Potency Outcome Based On Patient's Age



At 12 months:

<55 yrs - 89.7%

66-65 yrs – 86.8%

>66 yrs - 85%

In <55 yrs patients, potency immediate and at 1 month was statistically significant

(Cochran-Armitage test)


Immediate

At 3 months


At 12 months



Oncologic and Functional Outcomes




Trifecta Rates



Challenging Surgical Anatomy

Tips & Tricks





Conclusions

- Robotic prostatectomy built on the principles of open surgery can be a quality operation
- The procedure is effective in experienced hands
 - The procedure is in evolution
 - Many questions still need to be answered
 - 10 year data is not available yet, but there is a lot of very good data available



Key Principles To Achieving Quality Outcomes

- Follow the principles of open surgery
 - Do not cut corners!
- Minimize trauma to the tissues:
 - no thermal energy use during nerve preserving surgery
 - water tight anastomosis and preservation of the continence mechanisms
- Closely monitoring the outcomes
 - Validated questionnaires
 - self analysis of videos





Global Robotics Institute - Celebration

Robotic Radical Prostatectomy Lessons Learned: 3000 Cases





Vipul R. Patel MD
Director. Global Robotics Institute
Assoc Professor of Urology @ Univ of Central Florida
Director of Urologic Oncology

Journal Of Robotic Surgery

- Established in 2006
- Multi-specialty:
 - Urology, Gyn, ENT, Gen Surg, Cardiac
 - Allied health, executives
- Original articles, tips and tricks
- Video online
- Springer publisher







